Rigel partners TGF beta inhibitors with Bristol
Concurrent with its acquisition of Flexus Biosciences Inc. and related immune checkpoint assets, Bristol-Myers Squibb Co. signed a deal with Rigel Pharmaceuticals Inc. also in immuno-oncology. BMS received exclusive worldwide rights to Rigel's preclinical transforming growth factor (TGF) beta receptor kinase inhibitors.
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com